Maxcyte Inc (MXCT) Directors and Executive Officers

Officers & Directors

Maher Masoud
President, Chief Executive Officer and Director
(Principal Executive Officer)

Art Mandell
Director

Will Brooke
Director

Rekha Hemrajani
Director

Yasir Al-Wakeel
Director

Richard Douglas
Chairman of the Board of Directors

Stanley C. Erck
Director

Patrick J. Balthrop, Sr.
Director

John Johnston
Director

CohnRenzick LLP
We have served as the Company s auditor since

Douglas Swirsky
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer) ,

Maxcyte inc currently has 91 employees.

News about Maxcyte inc Key Personnel

MaxCyte at a Crossroads: Navigating Innovation Amidst Financial Headwinds

MaxCyte Inc.: A Legacy of Cell Engineering with Financial Challenges AheadMaxCyte, a prominent player in the biopharmaceutical landscape and a pioneer in cell engineering, recently released its preliminary unaudited financial results for the fourth quarter and full year ending December 31, 2024. Despite two decades of innovation, the company stands at a financial crossroads, grappling with significant operational losses and a notable return on investment (ROI) that lags behind its peers in the healthcare sector.Financial Overview: Losses and GainsMaxCyte reported a cumulative net loss of $36 million for the twelve months ending September 30, 2024, reflecting a negative ROI of -15.98%. This figure is alarming...

MaxCyte at 25: Navigating Innovation and Financial Challenges in the Quest for Genetic Cures,

IntroductionMaxCyte Inc. proudly commemorates 25 years of innovation in the field of cell engineering, a milestone marked by numerous advancements in cell and gene therapy since its inception in 1999. Despite its celebrated history, the company faces challenges, including a significant net loss reported for the second quarter of 2024. However, its recent strategic partnership with Kamau Therapeutics presents an optimistic outlook for the future.Celebrating Two Decades of InnovationSince 1999, MaxCyte has been at the forefront of non-viral cell engineering, enabling groundbreaking projects in cell and gene therapy. The company’s technological achievements, particularly its Flow Electroporation technology an...

MaxCyte Faces Financial Challenges as CEO Announces Retirement; Company Sets Focus on Revenue Guidance Update for 2023

MaxCyte Annou...